ABRx™ Antibiotic Resistance Panel Detects 17 Resistance Genes
Diatherix Laboratories, LLC has launched the ABRx™ Antibiotic Resistance Panel, a diagnostic test for detection of 17 antibiotic resistance genes. Used on properly collected specimens taken directly from the infectious process, the ABRx™ Panel can enhance result times and diagnostic accuracy, providing physicians and pharmacists with clinically important information to benefit both patient outcomes and hospital quality measures.
The ABRx™ Panel detects clinically problematic and prevalent antibiotic resistance genes that lead to resistance to some of the most commonly prescribed antibiotics: penicillins, cephalosporins, monobactams, carbapenems, macrolides and fluoroquinolones. The molecular identification of antibiotic resistance is an innovative approach in clinical diagnostics when compared to antibiotic susceptibility testing performed in routine laboratories.
More information about the ABRx™ Panel can be found in this technical bulletin.
Tags: Antibiotic Resistance
Date Published: October 11, 2016
Source article link: DIATHERIX Laboratories, Inc » company contact details
BIVDA Calls for Funding to Implement Rapid Diagnostics
Study Outlines ‘Perfect Storm’ that Led to Antibiotic Resistance Epidemic
Selective Growth of Colistin Resistant Bacteria on CHROMagar™ COL-APSE
New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Clindamycin (CD)